Showing posts with label Nicotine Oil. Show all posts
Showing posts with label Nicotine Oil. Show all posts

Monday, October 31, 2016

FDA Proposes Warning Labels on Liquid Nicotine Bottles

The Food and Drug Administration is expected to complete its April 2014 rules regulating e-cigarettes within the next two months.ENLARGE
The Food and Drug Administration is expected to complete its April 2014 rules regulating e-cigarettes within the next two months. PHOTO: TONY GENTILE/REUTERS
A proposal introduced on Tuesday by the Food and Drug Administration could result in warning labels and child-resistant packaging on bottles of liquid nicotine used in electronic cigarettes.
It is the first regulatory action on e-cigarettes the U.S. agency has announced since proposing regulations in April 2014 that would allow it to assume oversight of the $3.5 billion industry. The FDA is expected to complete those rules within the next two months. As part of the rules, it is also expected to restrict sales of battery-powered devices to anyone under 18 years old and require manufacturers to submit their products for federal approval.
The agency said on Tuesday that it would seek public comment for 60 days about whether bottles of liquid nicotine should require warning labels and childproof packaging in light of a recent increase in nicotine exposure and poisoning incidents. A January report by the California Department of Public Health said that reports of e-cigarette-related nicotine poisonings in young children in the state of California rose to 154 in 2014 from seven cases in 2012.
The FDA will weigh those comments before potentially proposing a rule and the agency would then take additional public comments before a rule is issued. By soliciting comments before it has oversight of the industry, the FDA is setting itself up to shorten the time it takes to complete a rule, which can take more than a year.
Federal and state lawmakers have urged the FDA this year to accelerate its push to regulate e-cigarettes. They have expressed alarm about nicotine poisonings and a report by the federal Centers for Disease Control and Prevention in April that e-cigarette use among teenagers tripled between 2013 and 2014.
The FDA will weigh comments on its proposal to put warning labels on liquid nicotine used in e-cigarettes before potentially proposing a rule.ENLARGE
The FDA will weigh comments on its proposal to put warning labels on liquid nicotine used in e-cigarettes before potentially proposing a rule. PHOTO: LUCAS JACKSON/REUTERS
In the absence of federal regulations, many states and cities have pushed forward with their own rules. More than 40 states have banned e-cigarette sales to minors and more than 100 cities have banned e-cigarette use indoors.
The FDA said earlier this year that it needed time to complete rules because e-cigarettes involve “complicated rule making.” The agency gained regulatory authority over cigarettes through the 2009 Family Smoking Prevention and Tobacco Control Act, but the act didn’t cover e-cigarettes and liquid nicotine products because they were just being introduced to the market.
The e-cigarette industry isn’t opposed to child-resistant packaging or warning labels, but e-cigarette advocates criticized the timing of the proposal because it came before the FDA has taken oversight of the industry. 

RE-cigarette advocates oppose the FDA treating e-cigarettes as tobacco products because they say e-cigarettes don’t contain tobacco leaf and they believe e-cigarettes can be used to help smokers quit cigarettes.

“This seems premature,” said Gregory Conley, president of the American Vaping Association, an industry funded advocacy group. “There are still numerous problems the FDA should be working out with their proposed regulations from last year before they contemplate new regulatory actions.”
Write to Tripp Mickle at

Monday, October 10, 2016

Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review


Electronic cigarettes are a recent development in tobacco harm reduction. They are marketed as less harmful alternatives to smoking. Awareness and use of these devices has grown exponentially in recent years, with millions of people currently using them. This systematic review appraises existing laboratory and clinical research on the potential risks from electronic cigarette use, compared with the well-established devastating effects of smoking tobacco cigarettes. Currently available evidence indicates that electronic cigarettes are by far a less harmful alternative to smoking and significant health benefits are expected in smokers who switch from tobacco to electronic cigarettes. Research will help make electronic cigarettes more effective as smoking substitutes and will better define and further reduce residual risks from use to as low as possible, by establishing appropriate quality control and standards.
Keywords: electronic cigarettes, e-liquid, e-vapor, harm reduction, nicotine, safety, tobacco


Complete tobacco cessation is the best outcome for smokers. However, the powerful addictive properties of nicotine and the ritualistic behavior of smoking create a huge hurdle, even for those with a strong desire to quit. Until recently, smokers were left with just two alternatives: either quit or suffer the harmful consequences of continued smoking. This gloomy scenario has allowed the smoking pandemic to escalate, with nearly 6 million deaths annually and a predicted death toll of 1 billion within the 21st century []. But a third choice, involving the use of alternative and much safer sources of nicotine with the goal to reduce smoking-related diseases is now available: tobacco harm reduction (THR) [].
Electronic cigarettes (ECs) are the newest and most promising products for THR []. They are electrically-driven devices consisting of the battery part (usually a lithium battery), and an atomizer where liquid is stored and is aerosolized by applying energy and generating heat to a resistance encircling a wick. The liquid used mainly consists of propylene glycol, glycerol, distilled water, flavorings (that may or may not be approved for food use) and nicotine. Consumers (commonly called ‘vapers’) may choose from several nicotine strengths, including non-nicotine liquids, and a countless list of flavors; this assortment is a characteristic feature that distinguishes ECs from any other THR products. Since their invention in 2003, there has been constant innovation and development of more efficient and appealing products. Currently, there are mainly three types of devices available [], depicted in Figure 1. (1) First-generation devices, generally mimicking the size and look of regular cigarettes and consisting of small lithium batteries and cartomizers (i.e. cartridges, which are usually prefilled with a liquid that bathes the atomizer). Batteries may be disposable (to be used once only) or rechargeable. (2) Second-generation devices, consisting mainly of higher-capacity lithium batteries and atomizers with the ability to refill them with liquid (sold in separate bottles). In the most recent atomizers you can simply change the atomizer head (resistance and wick) while keeping the body of the atomizer, thus reducing the operating costs. (3) Third-generation devices (also called ‘Mods’, from modifications), consisting of very large-capacity lithium batteries with integrated circuits that allow vapers to change the voltage or power (wattage) delivered to the atomizer. These devices can be combined with either second-generation atomizers or with rebuildable atomizers, where the consumers have the ability to prepare their own setup of resistance and wick.
Figure 1.
Examples of electronic cigarette devices currently available on the market.
Awareness and use (vaping) of ECs has increased exponentially in recent years. Data obtained from the HealthStyles survey showed that, in the US, awareness of ECs rose from 40.9–57.9% from 2010 to 2011, with EC use rising from 3.3–6.2% over the same time period []. In the United Kingdom, EC use in regular smokers increased from 2.7% in 2010 to 6.7% in 2012 []. Similar findings were obtained from the International Tobacco Control Four-Country Survey []. A recent prospective study in Swiss army recruits showed that 12% of smokers who tried ECs progressed to daily use []. It must be noted that this increase in EC use has occurred despite the concerns raised by public health authorities about the safety and appropriateness of using these products as alternatives to smoking [].
The popularity of ECs may be due to their ability to deal both with the physical (i.e. nicotine) and the behavioral component of smoking addiction. In particular, sensory stimulation [] and simulation of smoking behavior and cigarette manipulation [] are important determinants of a product’s effectiveness in reducing or completely substituting smoking. These features are generally absent in nicotine replacement therapies (NRTs) and oral medications for nicotine dependence, whereas ECs are unique in that they provide rituals associated with smoking behavior (e.g. hand-to-mouth movement, visible ‘smoke’ exhaled) and sensory stimulation associated with it []. This explains why these products can be effective in reducing consumption of tobacco smoking [] and are efficient as long-term substitutes of conventional cigarettes [].


For this systematic review (Figure 2), we searched the PubMed electronic database by using keywords related to ECs and/or their combination (e-cigarette, electronic cigarette, electronic nicotine delivery systems). We obtained a total of 354 results, and selected 41 studies we judged relevant to research on EC safety/risk profile. Reference lists from these studies were also examined to identify relevant articles. We searched additional information in abstracts presented at scientific congresses (respiratory, cardiovascular, tobacco control, toxicology), and in reports of chemical analyses on EC samples that were available online. We also looked for selected studies on chemicals related to EC ingredients (e.g. nicotine, propylene glycol, glycerol, cinnamaldehyde, microparticles emission, etc.), but not specifically evaluated in EC research. In total, 97 publications were found, from which 15 chemical analyses of single or a limited number of EC samples were excluded because they were discussed in a review paper []. In total, 114 studies are cited in this paper.
Figure 2.
Methodology for literature research and selection of studies.

Risk differences compared with conventional cigarettes and the issue of nicotine

Conventional cigarettes are the most common form of nicotine intake. Smoking-related diseases are pathophysiologically attributed to oxidative stress, activation of inflammatory pathways and the toxic effect of more than 4000 chemicals and carcinogens present in tobacco smoke []. In addition, each puff contains >1 × 1015 free radicals []. All of these chemicals are emitted mostly during the combustion process, which is absent in ECs. Although the addictive potential of nicotine and related compounds is largely documented [], much less dissemination has been given to the notion that nicotine does not contribute to smoking-related diseases. It is not classified as a carcinogen by the International Agency for Research on Cancer [] and does not promote obstructive lung disease. A major misconception, commonly supported even by physicians, is that nicotine promotes cardiovascular disease. However, it has been established that nicotine itself has minimal effect in initiating and promoting atherosclerotic heart disease []. It does not promote platelet aggregation [], does not affect coronary circulation [] and does not adversely alter the lipid profile []. An observational study of more than 33,000 smokers found no evidence of increased risk for myocardial infarction or acute stroke after NRT subscription, although follow up was only 56 days []. Up to 5 years of nicotine gum use in the Lung Health Study was unrelated to cardiovascular diseases or other serious side effects []. A meta-analysis of 35 clinical trials found no evidence of cardiovascular or other life-threatening adverse effects caused by nicotine intake []. Even in patients with established cardiovascular disease, nicotine use in the form of NRTs does not increase cardiovascular risk []. It is anticipated that any product delivering nicotine without involving combustion, such as the EC, would confer a significantly lower risk compared with conventional cigarettes and to other nicotine containing combustible products.
The importance of using nicotine in the long-term was recognized several years ago by Russell, indicating that the potential of nicotine delivery systems as long-term alternatives to tobacco should be explored in order to make the elimination of tobacco a realistic future target []. However, current regulations restrict the long-term use of pharmaceutical or recreational nicotine products (such as snus) []. In other words, nicotine intake has been demonized, although evidence suggests that, besides being useful in smoking cessation, it may even have beneficial effects in a variety of disorders such as Parkinson’s disease [], depression [], dementia [] and ulcerative colitis []. Obviously, the addictive potential is an important factor in any decision to endorse nicotine administration; however, it should be considered as slight ‘collateral damage’ with minimal impact to vapers’ health compared with the tremendous benefit of eliminating all disease-related substances coming from tobacco smoking. In fact, smokers are already addicted to nicotine; therefore the use of a ‘cleaner’ form of nicotine delivery would not represent any additional risk of addiction. Surveys have shown that ECs are used as long-term substitutes to smoking [; Etter and Bullen, 2012]. Although consumers try to reduce nicotine use with ECs, many are unable to completely stop its intake, indicating an important role for nicotine in the ECs’ effectiveness as a smoking substitute [].
Nicotine overdose or intoxication is unlikely to occur with vaping, since the amount consumed [] and absorbed [] is quite low. Moreover, although not yet proven, it is expected that vapers will self-titrate their nicotine intake in a similar way to tobacco cigarettes []. Last, but not least, there is evidence suggesting that nicotine cannot be delivered as fast and effectively from ECs compared to tobacco cigarettes []. Therefore, it seems that ECs have a huge theoretical advantage in terms of health risks compared with conventional cigarettes due to the absence of toxic chemicals that are generated in vast quantities by combustion. Furthermore, nicotine delivery by ECs is unlikely to represent a significant safety issue, particularly when considering they are intended to replace tobacco cigarettes, the most efficient nicotine delivery product.

Studies on the safety/risk profile of ECs

Findings on the safety/risk profile of ECs have just started to accumulate. However, this research must be considered work in progress given that the safety/risk of any product reflects an evolving body of knowledge and also because the product itself is undergoing constant development.
Existing studies about the safety/risk profile of ECs can be divided into chemical, toxicological and clinical studies (Table 1). Obviously, clinical studies are the most informative, but also the most demanding because of several methodological, logistical, ethical and financial challenges. In particular, exploring safety/risk profile in cohorts of well-characterized users in the long-term is required to address the potential of future disease development, but it would take hundreds of users to be followed for a substantial number of years before any conclusions are made. Therefore, most research is currently focused on in vitro effects, with clinical studies confined into evaluation of short-term use or pathophysiological mechanisms of smoking-related diseases.
Table 1.
Types of studies performed to determine safety and to estimate risk from EC use.

Chemical studies

Chemical studies are relatively simple and cheap to perform and provide quick results. However, there are several disadvantages with this approach. Research is usually focused on the known specific chemicals (generally those known to be toxic from studies of cigarette smoke) and fails to address unknown, potentially toxic contaminants that could be detected in the liquid or the emitted aerosol. Problems may also arise from the detection of the chemicals in flavors. Such substances, although approved for use in the food industry, have largely unknown effects when heated and inhaled; thus, information on the presence of such substances is difficult to interpret in terms of in vivo effects. In fact, chemical studies do not provide any objective information about the effects of use; they can only be used to calculate the risk based on theoretical models and on already established safety levels determined by health authorities. An overview of the chemical studies performed on ECs is displayed in Table 2.
Table 2.
Summary of chemical toxicity findings.
Laugesen performed the first studies evaluating the chemical composition of EC aerosols []. The temperature of the resistance of the tested EC was 54oC during activation, which is approximately 5–10% of the temperature of a burning tobacco cigarette. Toxic chemicals such as heavy metals, carcinogenic polycyclic aromatic hydrocarbons and phenols were not detected, with the exception of trivial amounts of mercury (0.17 ng per EC) and traces of formaldehyde and acetaldehyde. Laugesen evaluated emissions based on a toxicant emissions score and reported a score of 0 in ECs compared with a score of 100–134 for tobacco cigarettes (Figure 3). The US Food and Drug Administration (FDA) also performed chemical analyses on 18 commercially available products in 2009 []. They detected the presence of tobacco-specific nitrosamines (TSNAs) but did not declare the levels found. Small amounts of diethylene glycol were also found in one sample, which was unlikely to cause any harm from normal use. Another study identified small amounts of amino-tandalafil and rimonambant in EC liquids []. Subsequently, several laboratories performed similar tests, mostly on liquids, with Cahn and Siegel publishing a review on the chemical analyses of ECs and comparing the findings with tobacco cigarettes and other tobacco products []. They reported that TSNA levels were similar to those measured in pharmaceutical NRTs. The authors concluded that, based on chemical analysis, ECs are far less harmful compared with tobacco cigarettes. The most comprehensive study on TSNAs has been performed recently by a South Korean group, evaluating 105 liquids obtained from local retailers []. On average, they found 12.99 ηg TSNAs per ml of liquid, with the amount of daily exposure to the users estimated to be similar to users of NRTs []. The estimated daily exposure to nitrosamines from tobacco cigarettes (average consumption of 15 cigarettes per day) is estimated to be up to 1800 times higher compared with EC use (Table 3). Etter and colleagues evaluated the accuracy of nicotine labeling and the presence of nicotine impurities and degradation products in 20 EC liquid samples []. They found that nicotine levels were 85–121% of what was labeled, while nicotine degradation products were present at levels of 0–4.4%. Although in some samples the levels were higher than those specified in European Pharmacopoeia, they are not expected to cause any measurable harm to users.
Figure 3.
Toxic emissions score, adjusted for nicotine, for electronic cigarette and popular cigarette brands. (Reproduced with permission from )
Table 3.
Levels of nitrosamines found in electronic and tobacco cigarettes. Prepared based on information from  and .
Besides the evaluation for the presence of TSNAs, analyses have been performed for the detection of carbonyl compounds. It is known that the thermal degradation of propylene glycol and glycerol can lead to the emission of toxic compounds such as aldehydes []. Goniewicz and colleagues evaluated the emission of 15 carbonyls from 12 brands of ECs (mostly first-generation) []. In order to produce vapor, researchers used a smoking machine and followed a regime of 1.8-second puffs with a very short 10-second interpuff interval, which does not represent realistic use []; although the puff duration was low, interpuff interval was remarkably short, which could potentially lead to overheating. In addition, the same puff number was used in all devices tested, although there was a significant difference in the design and liquid content between devices. Despite these limitations, out of 15 carbonyls, only 3 were detected (formaldehyde, acetaldehyde and acrolein); levels were 9–450 times lower compared with emissions from tobacco cigarettes (derived from existing literature but not tested in the same experiment). Formaldehyde and acetaldehyde were also emitted from the nicotine inhalator, although at lower levels. In addition, they examined for the presence of 11 volatile organic carbons and found only trace levels of toluene (at levels from 0.2–6.3 µg per 150 puffs) and xylene (from 0.1–0.2 µg per 150 puffs) in 10 of the samples; toluene levels were 120 times lower compared with tobacco cigarettes (again derived from existing literature but not tested in the same experiment).
Given that ECs have several metal parts in direct contact with the e-liquid, it is quite obvious to expect some contamination with metals in the vapor. Goniewicz and colleagues examined samples for the presence of 12 metals and found nickel, cadmium and lead emitted []; the levels of nickel were similar to those present in a pharmaceutical nicotine inhalator, while lead and cadmium were present at 2–3 times higher levels compared with the inhalator. Still, the absolute levels were very low (few nanograms per 150 puffs).  focused their research on the presence of heavy metals and silicate particles emitted from ECs. They tested poor quality first-generation cartomisers and found several metals emitted in the aerosol of the EC, specifying that in some cases the levels were higher compared with conventional cigarettes. As mentioned earlier, it is not unusual to find trace levels of metals in the vapor generated by these products under experimental conditions that bear little relevance to their normal use; however, it is unlikely that such small amounts pose a serious threat to users’ health. Even if all the aerosol was absorbed by the consumer (which is not the case since most of the aerosol is visibly exhaled), an average user would be exposed to 4–40 times lower amounts for most metals than the maximum daily dose allowance from impurities in medicinal products []. Silicate particles were also found in the EC aerosol. Such particles come from the wick material, however the authors did not clarify whether crystalline silica oxide particles were found, which are responsible for respiratory disease. In total, the number of microparticles (< 1000 nm) estimated to be inhaled by EC users from 10 puffs were 880 times lower compared with one tobacco cigarette. Similar findings concerning microparticles were reported by Pellegrino and colleagues who found that, for each particulate matter fraction, conventional cigarettes released 6–18 times higher amounts compared with the EC tested [].
Burstyn has recently reviewed current data on the chemistry of aerosols and the liquids of ECs (including reports which were not peer-reviewed) and estimated the risk to consumers based on workplace exposure standards (i.e. Threshold Limit Values [TLVs]) []. After reviewing all available evidence, the author concluded that there was no evidence that vaping produced inhalable exposure to contaminants of aerosol that would warrant health concerns. He added that surveillance of use is recommended due to the high levels of propylene glycol and glycerol inhaled (which are not considered contaminants but ingredients of the EC liquid). There are limited data on the chronic inhalation of these chemicals by humans, although there is some evidence from toxicological studies (which are discussed later in this paper).
In conclusion, chemical studies have found that exposure to toxic chemicals from ECs is far lower compared with tobacco cigarettes. Besides comparing the levels of specific chemicals released from tobacco and ECs, it should be taken into consideration that the vast majority of the >4000 chemicals present in tobacco smoke are completely absent from ECs. Obviously, surveillance of use is warranted in order to objectively evaluate the in vivo effects and because the effects of inhaling flavoring substances approved for food use are largely unknown.

Toxicological studies

To date, only a handful of toxicological studies have been performed on ECs, mostly cytotoxicity studies on established cell lines. The cytotoxicity approach also has its flaws. Findings cannot be directly applied to the in vivo situation and there is always the risk of over- (as well as under-)estimating the interpretation of the toxic effects in these investigational models. An ample degree of results variability is to be expected from different cell lines and, sometimes, also within the same cell line. Comparing the potential cytotoxicity effects of EC vapor with those resulting from the exposure of cigarette smoke should be mandatory, but standards for vapor production and exposure protocols have not been clearly defined.
Bahl and colleagues [] performed cytotoxicity tests on 36 EC liquids, in human embryonic stem cells, mouse neural stem cells and human pulmonary fibroblasts and found that stem cells were more sensitive to the effects of the liquids, with 15 samples being moderately cytotoxic and 12 samples being highly cytotoxic. Propylene glycol and glycerol were not cytotoxic, but a correlation between cytotoxicity and the number and height of the flavoring peaks in high-performance liquid chromatography was noted. Investigations were just restricted to the effect of EC liquids and not to their vapors, thus limiting the importance of the study findings; this is not a trivial issue considering that the intended use of these products is by inhalation only and that it is unlikely that flavoring substances in the EC liquids will still be present in the aerosol in the same amount due to differences in evaporation temperature []. Regrettably, a set of experiments with cigarette smoke extracts as comparator was not included. Of note, the authors emphasized that the study could have underestimated the cytotoxicity by 100 times because when they added the EC liquids to the cell, medium final concentration was 1%. However, cells were cultured for 48 hours with continuous exposure to the liquid, while in real use the lungs come in contact with aerosol instead of liquid, the contact lasts for 1–2 seconds per puff and most of the aerosol is visibly exhaled. Finally, Cinnamon Ceylon, the liquid found to be mostly cytotoxic in this study, was not a refill liquid but a concentrated flavor which is not used in ECs unless it is diluted to 3–5%.
Romagna and colleagues [] performed the first cytotoxicity study of EC vapor on fibroblast cells. They used a standardized ISO 10993-5 protocol, which is used for regulatory purposes of medical devices and products. They tested the vapor of 21 liquid samples containing the same amount of nicotine (9 mg/ml), generated by a commercially available EC device. Cells were incubated for 24 hours with each of these vapors and with smoke from a conventional cigarette. Only one sample was found to be marginally cytotoxic, whereas cigarette smoke was highly cytotoxic (approximately 795% more cytotoxic), even when the extract was diluted up to 25% of the original concentration.
The same group also investigated the cytotoxic potential of 20 EC liquid samples in cardiomyoblasts []. Vapor was produced by using a commercially available EC device. Samples contained a wide range of nicotine concentrations. A base liquid mixture of propylene glycol and glycerol (no nicotine and no flavorings) was also included as an additional experimental control. Four of the samples examined were made by using cured tobacco leaves in a steeping process, allowing them to impregnate a mixture of propylene glycol and glycerol for several days before being filtered and bottled for use. Of note, this was the first study which evaluated a limited number of samples with an EC device delivering higher voltage and energy to the atomizer (third-generation device). In total, four samples were found to be cytotoxic; three of them were liquids made by using cured tobacco leaves, with cytotoxicity observed at both 100% and 50% extract concentration, while one sample (cinnamon flavor) was marginally cytotoxic at 100% extract concentration only. In comparison, smoke from three tobacco cigarettes was highly cytotoxic, with toxicity observed even when the extract was diluted to 12.5%. The samples made with tobacco leaves were three times less cytotoxic compared with cigarette smoke; this was probably due to the absence of combustion and the significantly lower temperature of evaporation in EC use. Concerning high-voltage EC use, the authors found slightly reduced cell viability without any of the samples being cytotoxic according to the ISO 10993-5 definition. Finally, no association between cell survival and the amount of nicotine present in the liquids was noted.
A recent study evaluated in more detail the cytotoxic potential of eight cinnamon-flavored EC liquids in human embryonic stem cells and human pulmonary fibroblasts []. The authors found that the flavoring substance predominantly present was cinnamaldehyde, which is approved for food use. They observed significant cytotoxic effects, mostly on stem cells but also on fibroblasts, with cytotoxicity associated with the amount of cinnamaldehyde present in the liquid. However, major methodological issues arose from this study. Once again, cytotoxicity was just restricted to EC liquids and not to their vapors. Moreover, the authors mentioned that the amount of cinnamaldehyde differed between liquids by up to 100 times, and this raises the suspicion of testing concentrated flavor rather than refills. By searching the internet and contacting manufacturers, based on the names of samples and suppliers mentioned in the manuscript, it was found that at least four of their samples were not refills but concentrated flavors. Surprisingly, the levels of cinnamaldehyde found to be cytotoxic were about 400 times lower than those currently approved for use []  

HVAC boot cleared of Asbestos in Los Angeles